Latest From Servier SA
In a case that has parallels with that of Servier’s diabetes drug Mediator, Sanofi has been indicted over its alleged lack of transparency over the birth defects associated with use of its valproate drug in pregnant women.
Scrip spoke with R&D head David Reese about improving R&D timelines and success rates, including through the use of genomics and proteomics, as data readouts near for key drugs in big indications.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
Novel therapeutic strategies for Parkinson’s disease have brought a renewed sense of optimism to those researching this neurodegenerative disorder. Numerous treatment avenues are being explored, including small molecules, gene therapy, cell therapy and medical devices to stimulate nerves deep in the brain. Digital also gets a look-in, being useful for analyzing gait and other symptoms, and addressing both mental and physical issues.
- Therapeutic Areas
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- Servier SA
- Senior Management
Olivier Laureau, CEO
Emmanuel Canet, Sr. EVP, R&D
- Contact Info
Phone: (33) 55 72 60 00
35 rue de Verdun
Suresnes Cedex, 92284
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.